Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• Chronic pam is a major contributor to disability m the industrialized world and is the cause of an untold amount of suffe ⁇ ng
• opioid analgesics being the current drugs of choice Lnhilst. This class of compounds produces several undesirable side effects including respiratory depression, constipation, and the development of tolerance and dependence
• Opioids are de ⁇ ved from the opium poppy papa ⁇ a sommferwn and include drugs such as morphine, codeine and semi-synthetic compounds de ⁇ ved from them and from thebame, another component of the opium poppy It was hypothesized that the opioids de ⁇ ved their therapeutic effect b ⁇ interacting with specific receptor sites in the body Later expe ⁇ ments led to the belief that there were more than one receptor site in the body, in explanation for the fact that the synthetic compound nalorphine provides analgesic activity while at the same time, antagonizes the analgesic effect of morphine
• ORLl receptor presents an opportunity in drug discovery for novel compounds which can be administered for pam management or other syndromes modulated by this receptor
• It is another object of the present invention to provide a method of modulating a response from opioid receptors comprising administe ⁇ ng a compound having a binding affinity for the ORLl receptor of less than 500 K, (nM) and a binding affinity for the mu receptor of less than 25 K, (nM)
• the compound has a binding affinity for the mu receptor of less than 25 K, (nM)
• the present invention in certain embodiments comprises compounds having the general formula (I)
• A is a saturated, unsaturated or partially unsaturated ⁇ ng
• Xi is selected from the group consisting of a bond, C ⁇ ⁇ o branched or straight alkyl, alkenyl. alkynylene optionally substituted with 1-3 halogen, oxo or phenyl groups, said phenyl group optionally substituted with 1-3 halogen or C, ⁇ o alkyl groups,
• Ri is selected from the group consisting of hydrogen, C 12 cycloalkyl, C 3 12 cycloalkenyl, a monocychc, bicychc or t ⁇ cychc aryl or heteroaryl ⁇ ng, a heteromonocychc ⁇ ng, and a heterobicyc c ring system, wherein said C 3 12 cycloalkyl, C-, 12 cycloalkenyl, monocychc.
• bicychc or t ⁇ cyclic aryl or heteroaryl ring, heteromonocychc ring, and heterobicychc ring system are optionally substituted with 1 -3 substituents selected from the group consisting of halogen, C 0 alkyl, nitro, t ⁇ fluoromethyl, phenyl, benzyl, phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy and benzyloxv are optionally substituted with halogen or C ⁇ 10 alkyl,
• R 2 is selected from the group consisting of C M O alkyl, C ⁇ ⁇ 2 cycloalkyl and halogen, said alkyl and cycloalkyl substituted with an oxo group, and
• R 3 and R4 are independently selected from the group consisting of hydrogen, hydroxy,
• Ci 3 alkoxy Ci 1 carbonyl and halogen; and pharmaceutically acceptable salts thereof
• A has one double bond at the 1 ,2 position
• X 1 R 1 is not hydrogen
• A has one double bond at the 1,2 position
• Xi is selected from a bond, methyl, ethyl or propyl
• Ri is a t ⁇ cyclic aryl ⁇ ng, preferably dibenzocycloheptyl
• Ri is a cycloalkyl, preferably cyclopentyl, cyclohexyl or cycloheptyl, wherein the cycloalkyl is optionally substituted with a C ⁇ 3 alkyl.
• Ri is a monocychc aryl ⁇ ng, preferably phenyl, wherein the aryl ring is optionally substituted with a halogen, alkyl, phenyl or benzyloxy
• Ri is selected from napthyl, benzyloxyphenyl, decahydronaphyl, 1.3 hydro-mdene, propylhexane, cyclodecyl, biphenylmethyl, phenylethyl, cyclooctyl, l,2,3,4,hydro-napthyl, 1-3 dimethyl-pentyl
• R 2 is a methyl, ethyl or propyl wherein the methyl ethyl and propyl are optionally substituted with an oxo group
• Ri and R 4 are both hydrogen
• alkyl means a linear or branched saturated aliphatic hydrocarbon group having a single radical and 1 -10 carbon atoms
• alkyl groups include methyl, propyl, isopropyl, butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and pentyl
• a branched alkyl means that one or more alkyl groups such as methyl, ethyl or propyl, replace one or both hydrogens in a -CLL- group of a linear alkyl chain
• cycloalkyl means a non-aromatic mono- or multicyc c hydrocarbon ring system having a single radical and 3-12 carbon atoms
• Exemplary monocychc cycloalkyl ⁇ ngs include cyclopropyl, cyclopentyl, and cyclohexyl
• Exemplary multicychc cycloalkyl ⁇ ngs include adamantyl and norbornyl
• alkenyl means a linear or branched aliphatic hydrocarbon group containing a carbon-carbon double bond having a single radical and 2-10 carbon atoms
• alkenyl groups include ethenyl, 1- and 2- propenyl, 1-, 2- and 3- butenyl, 3-methylbut-2-enyl, 2- propenyl, heptenyl, octenyl and decenyl
• cycloalkenyl means a non-aromatic monocychc or multicychc hydrocarbon ring system containing a carbon-carbon double bond having a single radical and 3 to 12 carbon atoms
• Exemplary monocychc cycloalkenyl ⁇ ngs include cyclopropenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl
• An exemplary multicychc cycloalkenyl ring is norbornenyl
• aryl means a carbocychc aromatic ⁇ ng system containing one, two or three rings which may be attached together in a pendent manner or fused, and containing a single radical
• aryl groups include phenyl and naphthyl
• heterocyclychc means cyclic compounds having one or more heteroatoms (atoms other than carbon) in the ⁇ ng, and having a single radical
• the ring may be saturated, partially saturated and unsaturated. and the heteroatoms may be selected from the group consisting of nitrogen, sulfur and oxygen
• saturated heterocychc radicals include saturated 3 to 6- membered heteromonocychc groups containing 1 to 4 nitrogen atoms, such as pyrrohdmyl, lmidazolidmyl, pipe ⁇ dino, piperazmyl, saturated 3- to 6- membered heteromonocychc groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, such as morphohnyl, saturated 3- to 6- membered heteromonocychc groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, such as thiazohdmyl
• partially saturated heterocychc radicals include dihydrothiophene, dihydropyran, and dihydrofuran
• heteroaryl means unsaturated heterocychc radicals, wherein heterocychc is as previously desc ⁇ bed
• exemplary heteroaryl groups include unsaturated 3 to 6 membered heteromonocychc groups containing 1 to 4 nitrogen atoms, such as pyrrolyl, py ⁇ dyl, py ⁇ midyl, and pyrazmyl, unsaturated condensed heterocychc groups containing 1 to 5 nitrogen atoms, such as mdolyl, qumolyl, isoquinolyl.
• heteroaryl also includes unsaturated heterocychc radicals, wherein heterocychc is as previously described, in which the
• patient includes both human and other mammals
• halogen includes fluoride, bromide, chloride, iodide or alabamide
• the invention disclosed herein is meant to encompass all pharmaceutically acceptable salts thereof of the disclosed compounds
• the pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium salt, potassium salt, secium salt and the like, alkaline earth metals such as calcium salt, magnesium salt and the like, organic amine salts such as t ⁇ ethylamme salt, py ⁇ dine salt, picolme salt, ethanolamine salt, t ⁇ ethanolamme salt, dicyclohexylamme salt, N,N'-d ⁇ benzylethylened ⁇ amme salt and the like, inorganic acid salts such as hydrochlo ⁇ de, hydrobromide, sulfate, phosphate and the like, organic acid salts such as formate, acetate, t ⁇ fluoroacetate, maleate, tartrate and the like, sulfonates such as methanesulfonate. benzenesulfonate, p-toluenesulfonate, and the like
• Prodrugs are considered to be any covalently bonded earners which release the active parent drug in vivo
• the invention disclosed herein is also meant to encompass the m vivo metabolic products of the disclosed compounds Such products may result for example from the oxidation, reduction, hydrolysis, amidation. este ⁇ fication and the like of the administered compound, p ⁇ ma ⁇ ly due to enzymatic processes
• the invention includes compounds produced by a process comprising contacting a compound of this invention with a mammal for a pe ⁇ od of time sufficient to yield a metabolic product thereof
• Such products typically are identified by prepa ⁇ ng a radiolabelled compound of the invention, administe ⁇ ng it parenterally in a detectable dose to an animal such as rat, mouse, guinea pig. monkey, or to man, allowing sufficient time for metabolism to occur and isolating its conversion products from the u ⁇ ne, blood or other biological samples
• the invention disclosed herein is also meant to encompass the disclosed compounds being lsotcpically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number
• isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, ⁇ , ' C, 14 C. 1 J N, 18 0, r O, j I P, j2 P, 3 'S, 1 F, and 3 ⁇ Cl, respectively
• Some of the compounds disclosed herein may contain one or more asymmet ⁇ c centers and may thus give rise to enantiomers, diastereomers.
• stereoisomers is a general term for all isomers of indiv idual molecules that differ only in the orientation of their atoms in space It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers)
• chiral center refers to a carbon atom to which four different groups are attached
• enantiomer or “enantiome ⁇ c” refers to a molecule that is nonsupe ⁇ mposeable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction
• racemic refers to a mixture of equal parts of enantiomers and which is optically inactive
• resolution refers to the separation or concentration or depletion of one of the two enantiome ⁇ c forms of a molecule
• Certain preferred compounds of fonnula I according to the invention include 1 -[ 1 -d ⁇ benzocycloheptyl-4-p ⁇ pe ⁇ dmyl]- 3-[ 1 -oxo-ethyl]- 1 ,3-d ⁇ hydro-2H- 1.3-benzam ⁇ dazol- 2-one, l-[l-(4-propylcyclohexane)-4-p ⁇ pe ⁇ d ⁇ nyl]- 3-[l -oxo-propyl]-l,3-d ⁇ hydro-2H-l,3- benzam ⁇ dazol-2-one, l-[l-(4-propylcyclohexane)-4-p ⁇ pe ⁇ dmyl]-3-[l-oxo-ethyl]-l,3-d ⁇ hydro-2H-l,3- benzam ⁇ dazol-2-one, l-[l-(4-propylcyclohexane)-4-p ⁇ pe ⁇ d ⁇ n
• the present invention is also directed to the following compounds l-[4-d ⁇ benzocycloheptyl-4-p ⁇ pe ⁇ dmyl]-l ,3-d ⁇ hydro-2H-l,3-benzam ⁇ dazol-2-one, 1 -[4-(4-propylcyclohexane)-4-p ⁇ pe ⁇ dmyl]- 1 ,3-d ⁇ hydro-2H- 1 ,3-benzam ⁇ dazol-2-one, l-[4-(4-propyl-l ,2-cyclohexene)-4-p ⁇ pendmyl-l,3-d ⁇ hydro-2H-l,3-benzam ⁇ dazol-2-one, l-[4-(4,4-d ⁇ fluorophenylbutyl)-4-p ⁇ pe ⁇ dmyl]-l,3-d ⁇ hydro-2H-l ,3-benzam ⁇ dazol-2-one, l-[4-(4-phenyl-phenylmethyl
• the compounds of the present invention can be administered to anyone requiring modulation of the opioid and ORLl receptors Administration may be orally, topically, by suppository, inhalation, or parenterally
• the present invention also encompasses all pharmaceutically acceptable salts of the foregoing compounds.
• acid addition salts of the presently claimed compounds may be prepared by reaction of the compounds with the appropriate acid via a variety of known methods
• Various oral dosage forms can be used, including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders and liquid forms such as emulsions, solution and suspensions
• the compounds of the present invention can be administered alone or can be combined with various pharmaceutically acceptable carriers and excipients known to those skilled in the art. including but not limited to diluents, suspending agents. solubihzers, binders, dismtegrants, preservatives, colo ⁇ ng agents, lub ⁇ cants and the like
• Liquid oral dosage forms include aqueous and nonaqueous solutions, emulsions, suspensions, and solutions and/or suspensions reconstituted from non-effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, colo ⁇ ng agents, and flavo ⁇ ng agents
• the compounds of the present invention may be, e g , in the form of an lsotonic ste ⁇ le solution
• they may be, e g , in the form of an lsotonic ste ⁇ le solution
• they mav be formulated into a dry aerosol or may be formulated into an aqueous or partially aqueous solution
• dosage forms may provide an immediate release of the compound in the gastrointestinal tract, or alternatively may provide a controlled and/or sustained release through the gastrointestinal tract
• a wide va ⁇ ety of controlled and/or sustained release formulations are well known to those skilled in the art, and are contemplated for use m connection with the formulations of the present invention
• the controlled and/or sustained release may be provided by, e g , a coating on the oral dosage form or by incorporating the compound(s) of the invention into a controlled and/or sustained release matrix
• the formulation for parenteral administration may be in the form of suspensions, solutions, emulsions in oily or aqueous vehicles, and such formulations may further comp ⁇ se pharmaceutically necessary additives such as stabilizing agents, suspending agents, dispersing agents, and the like
• the compounds of the invention may also be in the form of a powder for reconstitution as an injectable formulation
• the dose of the compounds of the present invention is dependent upon the affliction to be treated, the seventy of the symptoms, the route of administration, the frequency of the dosage interval, the presence of any delete ⁇ ous side-effects, and the particular compound utilized, among other things.
• Nociceptin affinity at the ORLl receptor for prefe ⁇ ed compounds was obtained using the following assay
• Membranes from recombmant HEK-293 cells expressing the human opioid receptorlike receptor (ORL-1 ) were prepared by lysing cells in ice-cold hypotomc buffer (2 5 mM MgCk 50 mM HEPES, pH 7 4) (10 ml/10 cm dish) followed by homogemzation with a tissue g ⁇ nder/teflon pestle Membranes were collected by cent ⁇ fugation at 30,000 x g for 15 mm at 4°C and pellets resuspended m hypotomc buffer to a final concentration of 1-3 mg/ml Protein concentrations were determined using the BioRad protein assay reagent w ith bovine serum albumen as standard Ahquots of the ORL-1 receptor membranes were stored at -80°C
• ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0 066 ⁇ g/ ⁇ l ORL-1 membrane protein. 10 ⁇ g/ml saponin, 3 ⁇ M GDP and 0 20 nM [ 3S S]GTP ⁇ S to binding buffer (100 mM NaCl, 10 mM MgCl 2 , 20 mM HEPES, pH 7 4) on ice
• the prepared membrane solution (190 ⁇ l/well) was transfened to 96-shallow well polypropylene plates containing 10 ⁇ l of 20x concentrated stock solutions of agonist prepared m DMSO Plates were incubated for 30 mm at room temperature with shaking Reactions were terminated by rapid filtration onto 96-well Umfilter GF/B filter plates (Packard) using a 96-well tissue harvester (Brandel) and followed by three filtration washes with 200 ⁇ l ice-cold binding buffer (10 mM NaH 2 P0 4 , 10
• Mu, kappa or delta opioid receptor membrane solution w as prepared by sequentially adding final concentrations of 0 075 ⁇ g/ ⁇ l of the desired membrane protein. 10 ⁇ g/ml saponm, 3 ⁇ M GDP and 0 20 nM [ 35 S]GTP ⁇ S to binding buffer (100 mM NaCl, 10 mM MgCl 2 , 20 mM HEPES, pH 7 4) on ice
• the prepared membrane solution (190 ⁇ l/well) was transfe ⁇ ed to 96-shallow well polypropylene plates containing 10 ⁇ l of 20x concentrated stock solutions of agonist prepared in DMSO Plates were incubated for 30 mm at room temperature with shaking Reactions were terminated by rapid filtration onto 96-well Umfilter GF/B filter plates (Packard) using a 96-well tissue harvester (Brandel) and followed by three filtration washes with 200 ⁇ l ice-cold binding buffer (10 mM NaH 2 P0 , 10 m

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22615490

Family Applications (1)

Country Status (8)

Cited By (19)

Families Citing this family (21)

Citations (2)

Family Cites Families (16)

• 2000
  • 2000-12-06 AU AU18169/01A patent/AU1816901A/en not_active Abandoned
  • 2000-12-06 JP JP2001541507A patent/JP2003524634A/ja active Pending
  • 2000-12-06 US US09/730,934 patent/US7456198B2/en not_active Expired - Lifetime
  • 2000-12-06 EP EP00980981A patent/EP1242085B1/en not_active Expired - Lifetime
  • 2000-12-06 HK HK03101335.9A patent/HK1049284B/en not_active IP Right Cessation
  • 2000-12-06 WO PCT/US2000/033019 patent/WO2001039775A1/en not_active Ceased
  • 2000-12-06 AT AT00980981T patent/ATE302770T1/de not_active IP Right Cessation
  • 2000-12-06 DE DE60022226T patent/DE60022226D1/de not_active Expired - Lifetime
• 2006
  • 2006-07-28 US US11/494,826 patent/US7678809B2/en not_active Expired - Fee Related
• 2007
  • 2007-06-15 JP JP2007158916A patent/JP2007277257A/ja active Pending

Patent Citations (2)

Also Published As

Similar Documents

Legal Events